Advertisement

Psychopharmacology in Pregnancy and Lactation

  • Jennifer L. PayneEmail author
Chapter
  • 19 Downloads

Abstract

Psychiatric illness during and immediately after pregnancy is common and potentially life-threatening. The proper management of psychiatric disorders during the peripartum time period remains controversial, though this is likely secondary to the stigma associated with psychiatric illness rather than a lack of data. Much of the early literature exploring the relationship between in utero psychiatric medication exposure and infant outcomes was flawed by inappropriate control populations, small sample sizes, and a lack of controls for confounds including psychiatric illness itself and associated health risk factors and behaviors. More recent studies are generally better designed to study whether infant outcomes are influenced by in utero medication exposure or by exposure to maternal psychiatric illness or both. The preponderance of the literature is reassuring regarding the safety of the use of most (not all) psychiatric medications during pregnancy and lactation. The preponderance of the literature also supports that unfavorable infant outcomes are associated with exposure to maternal mental illness. This chapter attempts to summarize what is currently known about the safety of psychiatric medications during pregnancy and lactation and, in addition, describes a clinical approach to designing a treatment plan for individual patients during this critical time for both mother and child.

Keywords

Pregnancy Postpartum Lactation Major depression Bipolar disorder Schizophrenia Anxiety Antidepressants Mood stabilizers Antipsychotics Benzodiazepines 

References

  1. 1.
    Kendell RE, Kemp IW. Winter-born v summer-born schizophrenics. Br J Psychiatry. 1987;151:499–505.CrossRefGoogle Scholar
  2. 2.
    Grof P, Robbins W, Alda M, Berghoefer A, Vojtechovsky M, Nilsson A, et al. Protective effect of pregnancy in women with lithium-responsive bipolar disorder. J Affect Disord. 2000;61(1–2):31–9.CrossRefGoogle Scholar
  3. 3.
    Marcus SM, Flynn HA, Blow FC, Barry KL. Depressive symptoms among pregnant women screened in obstetrics settings. J Women’s Health. 2003;12(4):373–80.  https://doi.org/10.1089/154099903765448880.CrossRefGoogle Scholar
  4. 4.
    Andersson L, Sundstrom-Poromaa I, Bixo M, Wulff M, Bondestam K, aStrom M. Point prevalence of psychiatric disorders during the second trimester of pregnancy: a population-based study. Am J Obstet Gynecol. 2003;189(1):148–54.CrossRefGoogle Scholar
  5. 5.
    Vesga-Lopez O, Blanco C, Keyes K, Olfson M, Grant BF, Hasin DS. Psychiatric disorders in pregnant and postpartum women in the United States. Arch Gen Psychiatry. 2008;65(7):805–15.  https://doi.org/10.1001/archpsyc.65.7.805.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Payne JL, Roy PS, Murphy-Eberenz K, Weismann MM, Swartz KL, McInnis MG, et al. Reproductive cycle-associated mood symptoms in women with major depression and bipolar disorder. J Affect Disord. 2007;99(1–3):221–9.  https://doi.org/10.1016/j.jad.2006.08.013.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Cox JL, Murray D, Chapman G. A controlled study of the onset, duration and prevalence of postnatal depression. Br J Psychiatry. 1993;163:27–31.CrossRefGoogle Scholar
  8. 8.
    Viguera AC, Tondo L, Koukopoulos AE, Reginaldi D, Lepri B, Baldessarini RJ. Episodes of mood disorders in 2,252 pregnancies and postpartum periods. Am J Psychiatry. 2011;168(11):1179–85.  https://doi.org/10.1176/appi.ajp.2011.11010148.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006;295(5):499–507.  https://doi.org/10.1001/jama.295.5.499.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Viguera AC, Nonacs R, Cohen LS, Tondo L, Murray A, Baldessarini RJ. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry. 2000;157(2):179–84.  https://doi.org/10.1176/appi.ajp.157.2.179.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Viguera AC, Whitfield T, Baldessarini RJ, Newport DJ, Stowe Z, Reminick A, et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry. 2007;164(12):1817–24; quiz 923.  https://doi.org/10.1176/appi.ajp.2007.06101639.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Robinson GE. Treatment of schizophrenia in pregnancy and postpartum. J Popul Ther Clin Pharmacol. 2012;19(3):e380–6.PubMedGoogle Scholar
  13. 13.
    Barnes TR. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25(5):567–620.  https://doi.org/10.1177/0269881110391123.CrossRefPubMedGoogle Scholar
  14. 14.
    Viguera AC, Baldessarini RJ, Hegarty JD, van Kammen DP, Tohen M. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry. 1997;54(1):49–55.CrossRefGoogle Scholar
  15. 15.
    Li D, Liu L, Odouli R. Presence of depressive symptoms during early pregnancy and the risk of preterm delivery: a prospective cohort study. Hum Reprod. 2009;24(1):146–53.  https://doi.org/10.1093/humrep/den342.CrossRefPubMedGoogle Scholar
  16. 16.
    Zuckerman B, Amaro H, Bauchner H, Cabral H. Depressive symptoms during pregnancy: relationship to poor health behaviors. Am J Obstet Gynecol. 1989;160(5 Pt 1):1107–11.CrossRefGoogle Scholar
  17. 17.
    Orr ST, Blazer DG, James SA, Reiter JP. Depressive symptoms and indicators of maternal health status during pregnancy. J Women’s Health. 2007;16(4):535–42.  https://doi.org/10.1089/jwh.2006.0116.CrossRefGoogle Scholar
  18. 18.
    Field T, Diego M, Hernandez-Reif M. Prenatal depression effects on the fetus and newborn: a review. Infant Behav Dev. 2006;29(3):445–55.  https://doi.org/10.1016/j.infbeh.2006.03.003.CrossRefPubMedGoogle Scholar
  19. 19.
    Field T, Diego M, Hernandez-Reif M. Prenatal depression effects and interventions: a review. Infant Behav Dev. 2010;33(4):409–18.  https://doi.org/10.1016/j.infbeh.2010.04.005.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Davis EP, Glynn LM, Dunkel Schetter C, Hobel C, Chicz-Demet A, Sandman CA. Corticotropin-releasing hormone during pregnancy is associated with infant temperament. Dev Neurosci. 2005;27(5):299–305.  https://doi.org/10.1159/000086709.CrossRefPubMedGoogle Scholar
  21. 21.
    Ashman SB, Dawson G, Panagiotides H, Yamada E, Wilkinson CW. Stress hormone levels of children of depressed mothers. Dev Psychopathol. 2002;14(2):333–49.CrossRefGoogle Scholar
  22. 22.
    Diego MA, Field T, Hernandez-Reif M, Cullen C, Schanberg S, Kuhn C. Prepartum, postpartum, and chronic depression effects on newborns. Psychiatry. 2004;67(1):63–80.CrossRefGoogle Scholar
  23. 23.
    Essex MJ, Klein MH, Cho E, Kalin NH. Maternal stress beginning in infancy may sensitize children to later stress exposure: effects on cortisol and behavior. Biol Psychiatry. 2002;52(8):776–84.CrossRefGoogle Scholar
  24. 24.
    Halligan SL, Herbert J, Goodyer IM, Murray L. Exposure to postnatal depression predicts elevated cortisol in adolescent offspring. Biol Psychiatry. 2004;55(4):376–81.  https://doi.org/10.1016/j.biopsych.2003.09.013.CrossRefPubMedGoogle Scholar
  25. 25.
    Brennan PA, Pargas R, Walker EF, Green P, Newport DJ, Stowe Z. Maternal depression and infant cortisol: influences of timing, comorbidity and treatment. J Child Psychol Psychiatry. 2008;49(10):1099–107.  https://doi.org/10.1111/j.1469-7610.2008.01914.x.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Grace SL, Evindar A, Stewart DE. The effect of postpartum depression on child cognitive development and behavior: a review and critical analysis of the literature. Arch Womens Ment Health. 2003;6(4):263–74.  https://doi.org/10.1007/s00737-003-0024-6.CrossRefPubMedGoogle Scholar
  27. 27.
    Ramoz LL, Patel-Shori NM. Recent changes in pregnancy and lactation labeling: retirement of risk categories. Pharmacotherapy. 2014;34(4):389–95.  https://doi.org/10.1002/phar.1385.CrossRefGoogle Scholar
  28. 28.
    Mosher WD, Bachrach CA. Understanding U.S. fertility: continuity and change in the National Survey of Family Growth, 1988-1995. Fam Plan Perspect. 1996;28(1):4–12.CrossRefGoogle Scholar
  29. 29.
    Finer LB, Zolna MR. Shifts in intended and unintended pregnancies in the United States, 2001-2008. Am J Public Health. 2014;104 Suppl 1:S43–8.  https://doi.org/10.2105/ajph.2013.301416.CrossRefPubMedGoogle Scholar
  30. 30.
    Einarson A. Abrupt discontinuation of psychotropic drugs following confirmation of pregnancy: a risky practice. J Obstet Gynaecol Can. 2005;27(11):1019–22.CrossRefGoogle Scholar
  31. 31.
    Seeman MV. Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry. 2004;161(8):1324–33.  https://doi.org/10.1176/appi.ajp.161.8.1324.CrossRefPubMedGoogle Scholar
  32. 32.
    Tracy TS, Venkataramanan R, Glover DD, Caritis SN. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am J Obstet Gynecol. 2005;192(2):633–9.  https://doi.org/10.1016/j.ajog.2004.08.030.CrossRefGoogle Scholar
  33. 33.
    Pavek P, Ceckova M, Staud F. Variation of drug kinetics in pregnancy. Curr Drug Metab. 2009;10(5):520–9.CrossRefGoogle Scholar
  34. 34.
    DeVane CL, Stowe ZN, Donovan JL, Newport DJ, Pennell PB, Ritchie JC, et al. Therapeutic drug monitoring of psychoactive drugs during pregnancy in the genomic era: challenges and opportunities. J Psychopharmacol. 2006;20(4 Suppl):54–9.  https://doi.org/10.1177/1359786806066054.CrossRefPubMedGoogle Scholar
  35. 35.
    Payne JL, Meltzer-Brody S. Antidepressant use during pregnancy: current controversies and treatment strategies. Clin Obstet Gynecol. 2009;52(3):469–82.  https://doi.org/10.1097/GRF.0b013e3181b52e20.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Stewart DE, Klompenhouwer JL, Kendell RE, van Hulst AM. Prophylactic lithium in puerperal psychosis. The experience of three centres. Br J Psychiatry. 1991;158:393–7.CrossRefGoogle Scholar
  37. 37.
    Cohen LS, Sichel DA, Robertson LM, Heckscher E, Rosenbaum JF. Postpartum prophylaxis for women with bipolar disorder. Am J Psychiatry. 1995;152(11):1641–5.CrossRefGoogle Scholar
  38. 38.
    Austin MP. Puerperal affective psychosis: is there a case for lithium prophylaxis? Br J Psychiatry. 1992;161:692–4.CrossRefGoogle Scholar
  39. 39.
    van Gent EM, Verhoeven WM. Bipolar illness, lithium prophylaxis, and pregnancy. Pharmacopsychiatry. 1992;25(4):187–91.  https://doi.org/10.1055/s-2007-1014404.CrossRefPubMedGoogle Scholar
  40. 40.
    Bergink V, Bouvy PF, Vervoort JS, Koorengevel KM, Steegers EA, Kushner SA. Prevention of postpartum psychosis and mania in women at high risk. Am J Psychiatry. 2012;169(6):609–15.  https://doi.org/10.1176/appi.ajp.2012.11071047.CrossRefPubMedGoogle Scholar
  41. 41.
    Sharma V, Smith A, Khan M. The relationship between duration of labour, time of delivery, and puerperal psychosis. J Affect Disord. 2004;83(2–3):215–20.  https://doi.org/10.1016/j.jad.2004.04.014.CrossRefPubMedGoogle Scholar
  42. 42.
    Sharma V. Role of sleep loss in the causation of puerperal psychosis. Med Hypotheses. 2003;61(4):477–81.CrossRefGoogle Scholar
  43. 43.
    Clark CT, Klein AM, Perel JM, Helsel J, Wisner KL. Lamotrigine dosing for pregnant patients with bipolar disorder. Am J Psychiatry. 2013;170(11):1240–7.  https://doi.org/10.1176/appi.ajp.2013.13010006.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Cunningham FGLK, Bloom SL, Hauth JC, Rouse DJ, Spong CY, editors. Williams obstetricas. New York: McGraw Hill; 2010.Google Scholar
  45. 45.
    Hanley GE, Oberlander TF. The effect of perinatal exposures on the infant: antidepressants and depression. Best Pract Res Clin Obstet Gynaecol. 2014;28(1):37–48.  https://doi.org/10.1016/j.bpobgyn.2013.09.001.CrossRefPubMedGoogle Scholar
  46. 46.
    Byatt N, Hicks-Courant K, Davidson A, Levesque R, Mick E, Allison J, et al. Depression and anxiety among high-risk obstetric inpatients. Gen Hosp Psychiatry. 2014;36(6):644–9.  https://doi.org/10.1016/j.genhosppsych.2014.07.011.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med. 2007;356(26):2684–92.  https://doi.org/10.1056/NEJMoa066584.CrossRefPubMedGoogle Scholar
  48. 48.
    Rahimi R, Nikfar S, Abdollahi M. Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials. Reproductive Toxicol (Elmsford, NY). 2006;22(4):571–5.  https://doi.org/10.1016/j.reprotox.2006.03.019.CrossRefGoogle Scholar
  49. 49.
    Addis A, Koren G. Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies. Psychol Med. 2000;30(1):89–94.CrossRefGoogle Scholar
  50. 50.
    Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf. 2005;14(12):823–7.  https://doi.org/10.1002/pds.1084.CrossRefGoogle Scholar
  51. 51.
    O’Brien L, Einarson TR, Sarkar M, Einarson A, Koren G. Does paroxetine cause cardiac malformations? J Obstet Gynaecol Can. 2008;30(8):696–701.CrossRefGoogle Scholar
  52. 52.
    Davis RL, Rubanowice D, McPhillips H, Raebel MA, Andrade SE, Smith D, et al. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf. 2007;16(10):1086–94.  https://doi.org/10.1002/pds.1462.CrossRefPubMedGoogle Scholar
  53. 53.
    Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner HA, Theis JG, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med. 1997;336(4):258–62.  https://doi.org/10.1056/nejm199701233360404.CrossRefPubMedGoogle Scholar
  54. 54.
    Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M, Sihn S, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA. 1993;269(17):2246–8.CrossRefGoogle Scholar
  55. 55.
    Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry. 2002;159(12):2055–61.  https://doi.org/10.1176/appi.ajp.159.12.2055.CrossRefPubMedGoogle Scholar
  56. 56.
    Ramos E, St-Andre M, Rey E, Oraichi D, Berard A. Duration of antidepressant use during pregnancy and risk of major congenital malformations. Br J Psychiatry. 2008;192(5):344–50.  https://doi.org/10.1192/bjp.bp.107.042523.CrossRefPubMedGoogle Scholar
  57. 57.
    Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med. 2010;40(10):1723–33.  https://doi.org/10.1017/s0033291709992194.CrossRefPubMedGoogle Scholar
  58. 58.
    Chun-Fai-Chan B, Koren G, Fayez I, Kalra S, Voyer-Lavigne S, Boshier A, et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol. 2005;192(3):932–6.  https://doi.org/10.1016/j.ajog.2004.09.027.CrossRefPubMedGoogle Scholar
  59. 59.
    Cole JA, Modell JG, Haight BR, Cosmatos IS, Stoler JM, Walker AM. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf. 2007;16(5):474–84.  https://doi.org/10.1002/pds.1296.CrossRefPubMedGoogle Scholar
  60. 60.
    Alwan S, Reefhuis J, Botto LD, Rasmussen SA, Correa A, Friedman JM. Maternal use of bupropion and risk for congenital heart defects. Am J Obstet Gynecol. 2010;203(1):52.e1–6.  https://doi.org/10.1016/j.ajog.2010.02.015.CrossRefGoogle Scholar
  61. 61.
    Byatt N, Deligiannidis KM, Freeman MP. Antidepressant use in pregnancy: a critical review focused on risks and controversies. Acta Psychiatr Scand. 2013;127(2):94–114.  https://doi.org/10.1111/acps.12042.CrossRefPubMedGoogle Scholar
  62. 62.
    Yonkers KA, Blackwell KA, Glover J, Forray A. Antidepressant use in pregnant and postpartum women. Annu Rev Clin Psychol. 2014;10:369–92.  https://doi.org/10.1146/annurev-clinpsy-032813-153626.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Chisolm MS, Payne JL. Management of psychotropic drugs during pregnancy. BMJ. 2016;532:h5918.  https://doi.org/10.1136/bmj.h5918.CrossRefPubMedGoogle Scholar
  64. 64.
    Huybrechts KF, Palmsten K, Avorn J, Cohen LS, Holmes LB, Franklin JM, et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med. 2014;370(25):2397–407.  https://doi.org/10.1056/NEJMoa1312828.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Wang S, Yang L, Wang L, Gao L, Xu B, Xiong Y. Selective Serotonin Reuptake Inhibitors (SSRIs) and the risk of congenital heart defects: a meta-analysis of prospective cohort studies. J Am Heart Assoc. 2015;4(5)  https://doi.org/10.1161/jaha.114.001681.
  66. 66.
    Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354(6):579–87.  https://doi.org/10.1056/NEJMoa052744.CrossRefPubMedGoogle Scholar
  67. 67.
    Andrade SE, McPhillips H, Loren D, Raebel MA, Lane K, Livingston J, et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf. 2009;18(3):246–52.  https://doi.org/10.1002/pds.1710.CrossRefPubMedGoogle Scholar
  68. 68.
    Wichman CL, Moore KM, Lang TR, St Sauver JL, Heise RH Jr, Watson WJ. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc. 2009;84(1):23–7.CrossRefGoogle Scholar
  69. 69.
    Wilson KL, Zelig CM, Harvey JP, Cunningham BS, Dolinsky BM, Napolitano PG. Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am J Perinatol. 2011;28(1):19–24.  https://doi.org/10.1055/s-0030-1262507.CrossRefPubMedGoogle Scholar
  70. 70.
    Kallen B, Olausson PO. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf. 2008;17(8):801–6.  https://doi.org/10.1002/pds.1570.CrossRefPubMedGoogle Scholar
  71. 71.
    Kieler H, Artama M, Engeland A, Ericsson O, Furu K, Gissler M, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ. 2012;344:d8012.  https://doi.org/10.1136/bmj.d8012.CrossRefPubMedGoogle Scholar
  72. 72.
    Huybrechts KF, Bateman BT, Palmsten K, Desai RJ, Patorno E, Gopalakrishnan C, et al. Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA. 2015;313(21):2142–51.  https://doi.org/10.1001/jama.2015.5605.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Hageman JR, Adams MA, Gardner TH. Persistent pulmonary hypertension of the newborn. Trends in incidence, diagnosis, and management. Am J Dis Child (1960). 1984;138(6):592–5.CrossRefGoogle Scholar
  74. 74.
    Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Mitchell AA. Risk factors for persistent pulmonary hypertension of the newborn. Pediatrics. 2007;120(2):e272–82.  https://doi.org/10.1542/peds.2006-3037.CrossRefPubMedGoogle Scholar
  75. 75.
    Croen LA, Grether JK, Yoshida CK, Odouli R, Hendrick V. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry. 2011;68(11):1104–12.  https://doi.org/10.1001/archgenpsychiatry.2011.73.CrossRefPubMedGoogle Scholar
  76. 76.
    Rai D, Lee BK, Dalman C, Golding J, Lewis G, Magnusson C. Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study. BMJ. 2013;346:f2059.  https://doi.org/10.1136/bmj.f2059.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Hviid A, Melbye M, Pasternak B. Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism. N Engl J Med. 2013;369(25):2406–15.  https://doi.org/10.1056/NEJMoa1301449.CrossRefPubMedGoogle Scholar
  78. 78.
    Sujan AC, Rickert ME, Oberg AS, Quinn PD, Hernandez-Diaz S, Almqvist C, et al. Associations of maternal antidepressant use during the first trimester of pregnancy with preterm birth, small for gestational age, autism spectrum disorder, and attention-deficit/hyperactivity disorder in offspring. JAMA. 2017;317(15):1553–62.  https://doi.org/10.1001/jama.2017.3413.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Brown HK, Ray JG, Wilton AS, Lunsky Y, Gomes T, Vigod SN. Association between serotonergic antidepressant use during pregnancy and autism spectrum disorder in children. JAMA. 2017;317(15):1544–52.  https://doi.org/10.1001/jama.2017.3415.CrossRefPubMedGoogle Scholar
  80. 80.
    Oberlander TF, Zwaigenbaum L. Disentangling maternal depression and antidepressant use during pregnancy as risks for autism in children. JAMA. 2017;317(15):1533–4.  https://doi.org/10.1001/jama.2017.3414.CrossRefPubMedGoogle Scholar
  81. 81.
    Andrade C. Antidepressant exposure during pregnancy and risk of autism in the offspring, 1: meta-review of meta-analyses. J Clin Psychiatry. 2017;78(8):e1047–e51.  https://doi.org/10.4088/JCP.17f11903.CrossRefPubMedGoogle Scholar
  82. 82.
    Huybrechts KF, Sanghani RS, Avorn J, Urato AC. Preterm birth and antidepressant medication use during pregnancy: a systematic review and meta-analysis. PLoS One. 2014;9(3):e92778.  https://doi.org/10.1371/journal.pone.0092778.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Yonkers KA, Norwitz ER, Smith MV, Lockwood CJ, Gotman N, Luchansky E, et al. Depression and serotonin reuptake inhibitor treatment as risk factors for preterm birth. Epidemiology. 2012;23(5):677–85.  https://doi.org/10.1097/EDE.0b013e31825838e9.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Pearlstein T. Use of psychotropic medication during pregnancy and the postpartum period. Women’s Health (Lond Engl). 2013;9(6):605–15.  https://doi.org/10.2217/whe.13.54.CrossRefGoogle Scholar
  85. 85.
    Jarde A, Morais M, Kingston D, Giallo R, MacQueen GM, Giglia L, et al. Neonatal outcomes in women with untreated antenatal depression compared with women without depression: a systematic review and meta-analysis. JAMA Psychiat. 2016;  https://doi.org/10.1001/jamapsychiatry.2016.0934.CrossRefGoogle Scholar
  86. 86.
    Webster PA. Withdrawal symptoms in neonates associated with maternal antidepressant therapy. Lancet. 1973;2(7824):318–9.CrossRefGoogle Scholar
  87. 87.
    Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005;293(19):2372–83.  https://doi.org/10.1001/jama.293.19.2372.CrossRefGoogle Scholar
  88. 88.
    Oberlander TF, Misri S, Fitzgerald CE, Kostaras X, Rurak D, Riggs W. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry. 2004;65(2):230–7.CrossRefGoogle Scholar
  89. 89.
    Salisbury AL, O’Grady KE, Battle CL, Wisner KL, Anderson GM, Stroud LR, et al. The roles of maternal depression, serotonin reuptake inhibitor treatment, and concomitant benzodiazepine use on infant neurobehavioral functioning over the first postnatal month. Am J Psychiatry. 2016;173(2):147–57.  https://doi.org/10.1176/appi.ajp.2015.14080989.CrossRefPubMedGoogle Scholar
  90. 90.
    Alwan S, Reefhuis J, Rasmussen SA, Friedman JM. Patterns of antidepressant medication use among pregnant women in a United States population. J Clin Pharmacol. 2011;51(2):264–70.  https://doi.org/10.1177/0091270010373928.CrossRefPubMedGoogle Scholar
  91. 91.
    Kronenfeld N, Berlin M, Shaniv D, Berkovitch M. Use of psychotropic medications in breastfeeding women. Birth Defects Res. 2017;109(12):957–97.  https://doi.org/10.1002/bdr2.1077.CrossRefPubMedGoogle Scholar
  92. 92.
    Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv (Washington, DC). 2002;53(1):39–49.  https://doi.org/10.1176/appi.ps.53.1.39.CrossRefGoogle Scholar
  93. 93.
    Lin AE, Peller AJ, Westgate MN, Houde K, Franz A, Holmes LB. Clonazepam use in pregnancy and the risk of malformations. Birth Defects Res A Clin Mol Teratol. 2004;70(8):534–6.  https://doi.org/10.1002/bdra.20051.CrossRefPubMedGoogle Scholar
  94. 94.
    Oberlander TF, Gingrich JA, Ansorge MS. Sustained neurobehavioral effects of exposure to SSRI antidepressants during development: molecular to clinical evidence. Clin Pharmacol Ther. 2009;86(6):672–7.  https://doi.org/10.1038/clpt.2009.201.CrossRefPubMedPubMedCentralGoogle Scholar
  95. 95.
    Holmes LB, Hernandez-Diaz S. Newer anticonvulsants: lamotrigine, topiramate and gabapentin. Birth Defects Res A Clin Mol Teratol. 2012;94(8):599–606.  https://doi.org/10.1002/bdra.23028.CrossRefPubMedGoogle Scholar
  96. 96.
    Molgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA. 2011;305(19):1996–2002.  https://doi.org/10.1001/jama.2011.624.CrossRefPubMedGoogle Scholar
  97. 97.
    Fujii H, Goel A, Bernard N, Pistelli A, Yates LM, Stephens S, et al. Pregnancy outcomes following gabapentin use: results of a prospective comparative cohort study. Neurology. 2013;80(17):1565–70.  https://doi.org/10.1212/WNL.0b013e31828f18c1.CrossRefPubMedPubMedCentralGoogle Scholar
  98. 98.
    Gilboa SM, Ailes EC, Rai RP, Anderson JA, Honein MA. Antihistamines and birth defects: a systematic review of the literature. Expert Opin Drug Saf. 2014;13(12):1667–98.  https://doi.org/10.1517/14740338.2014.970164.CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Fejzo MS, Magtira A, Schoenberg FP, MacGibbon K, Mullin P, Romero R, et al. Antihistamines and other prognostic factors for adverse outcome in hyperemesis gravidarum. Eur J Obstet Gynecol Reprod Biol. 2013;170(1):71–6.  https://doi.org/10.1016/j.ejogrb.2013.04.017.CrossRefPubMedPubMedCentralGoogle Scholar
  100. 100.
    Etwel F, Faught LH, Rieder MJ, Koren G. The risk of adverse pregnancy outcome after first trimester exposure to H1 antihistamines: a systematic review and meta-analysis. Drug Saf. 2017;40(2):121–32.  https://doi.org/10.1007/s40264-016-0479-9.CrossRefPubMedGoogle Scholar
  101. 101.
    Okun ML, Ebert R, Saini B. A review of sleep-promoting medications used in pregnancy. Am J Obstet Gynecol. 2015;212(4):428–41.  https://doi.org/10.1016/j.ajog.2014.10.1106.CrossRefPubMedGoogle Scholar
  102. 102.
    Reis M, Kallen B. Combined use of selective serotonin reuptake inhibitors and sedatives/hypnotics during pregnancy: risk of relatively severe congenital malformations or cardiac defects. A register study. BMJ Open. 2013;3(2)  https://doi.org/10.1136/bmjopen-2012-002166.CrossRefGoogle Scholar
  103. 103.
    Khazaie H, Ghadami MR, Knight DC, Emamian F, Tahmasian M. Insomnia treatment in the third trimester of pregnancy reduces postpartum depression symptoms: a randomized clinical trial. Psychiatry Res. 2013;210(3):901–5.  https://doi.org/10.1016/j.psychres.2013.08.017.CrossRefPubMedGoogle Scholar
  104. 104.
    Cunnington M, Tennis P. Lamotrigine and the risk of malformations in pregnancy. Neurology. 2005;64(6):955–60.  https://doi.org/10.1212/01.wnl.0000154515.94346.89.CrossRefGoogle Scholar
  105. 105.
    Holmes LB, Baldwin EJ, Smith CR, Habecker E, Glassman L, Wong SL, et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology. 2008;70(22 Pt 2):2152–8.  https://doi.org/10.1212/01.wnl.0000304343.45104.d6.CrossRefPubMedGoogle Scholar
  106. 106.
    Dolk H, Jentink J, Loane M, Morris J, de Jong-van den Berg LT. Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Neurology. 2008;71(10):714–22.  https://doi.org/10.1212/01.wnl.0000316194.98475.d8.CrossRefGoogle Scholar
  107. 107.
    Bromley RL, Mawer GE, Briggs M, Cheyne C, Clayton-Smith J, Garcia-Finana M, et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. J Neurol Neurosurg Psychiatry. 2013;84(6):637–43.  https://doi.org/10.1136/jnnp-2012-304270.CrossRefPubMedPubMedCentralGoogle Scholar
  108. 108.
    Christensen J, Gronborg TK, Sorensen MJ, Schendel D, Parner ET, Pedersen LH, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA. 2013;309(16):1696–703.  https://doi.org/10.1001/jama.2013.2270.CrossRefPubMedPubMedCentralGoogle Scholar
  109. 109.
    Casassus B. France bans sodium valproate use in case of pregnancy. Lancet. 2017;390(10091):217.  https://doi.org/10.1016/s0140-6736(17)31866-4.CrossRefPubMedGoogle Scholar
  110. 110.
    Cohen LS, Friedman JM, Jefferson JW, Johnson EM, Weiner ML. A reevaluation of risk of in utero exposure to lithium. JAMA. 1994;271(2):146–50.CrossRefGoogle Scholar
  111. 111.
    Jacobson SJ, Jones K, Johnson K, Ceolin L, Kaur P, Sahn D, et al. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet. 1992;339(8792):530–3.CrossRefGoogle Scholar
  112. 112.
    Bogen DL, Sit D, Genovese A, Wisner KL. Three cases of lithium exposure and exclusive breastfeeding. Arch Womens Ment Health. 2012;15(1):69–72.  https://doi.org/10.1007/s00737-012-0257-3.CrossRefPubMedPubMedCentralGoogle Scholar
  113. 113.
    Webb RT, Howard L, Abel KM. Antipsychotic drugs for non-affective psychosis during pregnancy and postpartum. Cochrane Database Syst Rev. 2004;2:CD004411.  https://doi.org/10.1002/14651858.CD004411.pub2.CrossRefGoogle Scholar
  114. 114.
    Khalifeh H, Dolman C, Howard LM. Safety of psychotropic drugs in pregnancy. BMJ. 2015;350:h2260.  https://doi.org/10.1136/bmj.h2260.CrossRefPubMedGoogle Scholar
  115. 115.
    Einarson A, Boskovic R. Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract. 2009;15(3):183–92.  https://doi.org/10.1097/01.pra.0000351878.45260.94.CrossRefPubMedGoogle Scholar
  116. 116.
    Einarson A, Einarson TR. Maternal use of antipsychotics in early pregnancy: little evidence of increased risk of congenital malformations. Evid Based Ment Health. 2009;12(1):29.  https://doi.org/10.1136/ebmh.12.1.29.CrossRefPubMedGoogle Scholar
  117. 117.
    Seeman MV. Clinical interventions for women with schizophrenia: pregnancy. Acta Psychiatr Scand. 2013;127(1):12–22.  https://doi.org/10.1111/j.1600-0447.2012.01897.x.CrossRefPubMedGoogle Scholar
  118. 118.
    Newport DJ, Calamaras MR, DeVane CL, Donovan J, Beach AJ, Winn S, et al. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry. 2007;164(8):1214–20.  https://doi.org/10.1176/appi.ajp.2007.06111886.CrossRefGoogle Scholar
  119. 119.
    Newham JJ, Thomas SH, MacRitchie K, McElhatton PR, McAllister-Williams RH. Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study. Br J Psychiatry. 2008;192(5):333–7.  https://doi.org/10.1192/bjp.bp.107.041541.CrossRefPubMedGoogle Scholar
  120. 120.
    Reis M, Kallen B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol. 2008;28(3):279–88.  https://doi.org/10.1097/JCP.0b013e318172b8d5.CrossRefPubMedGoogle Scholar
  121. 121.
    Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull. 2010;36(3):518–44.  https://doi.org/10.1093/schbul/sbn107.CrossRefGoogle Scholar
  122. 122.
    Paton C. Prescribing in pregnancy. Br J Psychiatry. 2008;192(5):321–2.  https://doi.org/10.1192/bjp.bp.108.049585.CrossRefPubMedGoogle Scholar
  123. 123.
    Coppola D, Russo LJ, Kwarta RF Jr, Varughese R, Schmider J. Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes. Drug Saf. 2007;30(3):247–64.CrossRefGoogle Scholar
  124. 124.
    Altshuler LL, Cohen L, Szuba MP, Burt VK, Gitlin M, Mintz J. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry. 1996;153(5):592–606.CrossRefGoogle Scholar
  125. 125.
    Thiels C. Pharmacotherapy of psychiatric disorder in pregnancy and during breastfeeding: a review. Pharmacopsychiatry. 1987;20(4):133–46.  https://doi.org/10.1055/s-2007-1017092.CrossRefGoogle Scholar
  126. 126.
    Peng M, Gao K, Ding Y, Ou J, Calabrese JR, Wu R, et al. Effects of prenatal exposure to atypical antipsychotics on postnatal development and growth of infants: a case-controlled, prospective study. Psychopharmacology. 2013;228(4):577–84.  https://doi.org/10.1007/s00213-013-3060-6.CrossRefGoogle Scholar
  127. 127.
    Johnson KC, LaPrairie JL, Brennan PA, Stowe ZN, Newport DJ. Prenatal antipsychotic exposure and neuromotor performance during infancy. Arch Gen Psychiatry. 2012;69(8):787–94.  https://doi.org/10.1001/archgenpsychiatry.2012.160.CrossRefPubMedPubMedCentralGoogle Scholar
  128. 128.
    Habermann F, Fritzsche J, Fuhlbruck F, Wacker E, Allignol A, Weber-Schoendorfer C, et al. Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study. J Clin Psychopharmacol. 2013;33(4):453–62.  https://doi.org/10.1097/JCP.0b013e318295fe12.CrossRefPubMedPubMedCentralGoogle Scholar
  129. 129.
    Communication FDS. Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns. 2011. http://www.fda.gov/Drugs/DrugSafety/ucm243903.htm#sa. Accessed 28 Apr 2015.
  130. 130.
    Drugs. AAoPCo. Use of psychoactive medication during pregnancy and possible effects on the fetus and newborn. Pediatrics. 2000;105(4 Pt 1):880–7.CrossRefGoogle Scholar
  131. 131.
    Brunner E, Falk DM, Jones M, Dey DK, Shatapathy CC. Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance. BMC Pharmacol Toxicol. 2013;14:38.  https://doi.org/10.1186/2050-6511-14-38.CrossRefPubMedPubMedCentralGoogle Scholar
  132. 132.
    Bolea-Alamanac BM, Green A, Verma G, Maxwell P, Davies SJ. Methylphenidate use in pregnancy and lactation: a systematic review of evidence. Br J Clin Pharmacol. 2014;77(1):96–101.  https://doi.org/10.1111/bcp.12138.CrossRefPubMedGoogle Scholar
  133. 133.
    Humphreys C, Garcia-Bournissen F, Ito S, Koren G. Exposure to attention deficit hyperactivity disorder medications during pregnancy. Can Fam Physician. 2007;53(7):1153–5.PubMedPubMedCentralGoogle Scholar
  134. 134.
    Dadashova R, Silverstone PH. Off-label use of atomoxetine in adults: is it safe? Ment Illn. 2012;4(2):e19.  https://doi.org/10.4081/mi.2012.e19.CrossRefPubMedPubMedCentralGoogle Scholar
  135. 135.
    Bro SP, Kjaersgaard MI, Parner ET, Sorensen MJ, Olsen J, Bech BH, et al. Adverse pregnancy outcomes after exposure to methylphenidate or atomoxetine during pregnancy. Clin Epidemiol. 2015;7:139–47.  https://doi.org/10.2147/clep.S72906.CrossRefPubMedPubMedCentralGoogle Scholar
  136. 136.
    Haervig KB, Mortensen LH, Hansen AV, Strandberg-Larsen K. Use of ADHD medication during pregnancy from 1999 to 2010: a Danish register-based study. Pharmacoepidemiol Drug Saf. 2014;23(5):526–33.  https://doi.org/10.1002/pds.3600.CrossRefGoogle Scholar
  137. 137.
    Pottegard A, Hallas J, Andersen JT, Lokkegaard EC, Dideriksen D, Aagaard L, et al. First-trimester exposure to methylphenidate: a population-based cohort study. J Clin Psychiatry. 2014;75(1):e88–93.  https://doi.org/10.4088/JCP.13m08708.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Psychiatry and Behavioral SciencesJohns Hopkins University School of Medicine, Women’s Mood Disorders CenterBaltimoreUSA

Personalised recommendations